X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KPL-404 (abiprubart) is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction. It is being evaluated for the treatment of Sjogren’s Disease.
Lead Product(s): Abiprubart
Therapeutic Area: Immunology Product Name: KPL-404
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
KPL-716 (vixarelimab) is an investigational fully human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ), which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation, and fibrosis.
Lead Product(s): Vixarelimab
Therapeutic Area: Dermatology Product Name: KPL-716
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $700.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement September 12, 2022
Details:
Genentech will focus on development of KPL-716 (vixarelimab) in fibrosis, where oncostatin M (OSM)-mediated pathogenesis is thought to be an important pathway for intervention in multiple fibrotic indications.
Lead Product(s): Vixarelimab
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: KPL-716
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $700.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement August 03, 2022
Details:
Ongoing Phase 3 study of mavrilimumab in COVID-19-related ARDS represents the fastest path to potential registration for the asset, and there remains a significant unmet need in these patients.
Lead Product(s): Mavrilimumab
Therapeutic Area: Infections and Infectious Diseases Product Name: KPL-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The US FDA has approved Kiniksa Pharmaceuticals’ interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) inhibitor Arcalyst (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older.
Lead Product(s): Rilonacept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arcalyst
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
Data showed an early signal of efficacy, with trends toward clinical improvement as well as lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab on top of corticosteroids, including dexamethasone, and/or remdesivir.
Lead Product(s): Mavrilimumab
Therapeutic Area: Infections and Infectious Diseases Product Name: KPL-301
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Vixarelimab is a fully-human monoclonal antibody that targets oncostatin M receptor beta. The Phase 2b trial is designed to investigate the efficacy, safety, and pharmacokinetics of vixarelimab in patients with prurigo nodularis.
Lead Product(s): Vixarelimab
Therapeutic Area: Dermatology Product Name: KPL-716
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Kiniksa expects to initiate a Phase 2b clinical trial of vixarelimab in prurigo nodularis, evaluating a range of once-monthly dose regimens, by the end of the year.
Lead Product(s): Vixarelimab
Therapeutic Area: Dermatology Product Name: KPL-716
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Mavrilimumab was well-tolerated; there were no drug-related serious adverse events, and the rates of drug-related treatment-emergent adverse events between mavrilimumab recipients and placebo recipients were similar.
Lead Product(s): Mavrilimumab
Therapeutic Area: Immunology Product Name: KPL-301
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The Phase 2a trial met its primary efficacy endpoint: there was a statistically significant reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) from baseline at Week 8 in vixarelimab recipients compared to placebo recipients.
Lead Product(s): Vixarelimab
Therapeutic Area: Dermatology Product Name: KPL-716
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
